文献速递白血病造血干细胞移植与细胞治疗

微滴数字PCR:监测和预后评估幼年型粒单核细胞白血病微小残留病的有效方法

Droplet digital PCR: An effective method for monitoring and prognostic evaluation of minimal residual disease in JMML.
PubMed 文献 · Br J Haematol · 2024-04-15

这项回顾性研究利用微滴数字PCR(ddPCR)监测32例幼年型粒单核细胞白血病(JMML)患者的微小残留病(MRD)。ddPCR比传统方法更早检测到复发表现,移植后1至3个月为检测分子复发的关键窗口,66.7%(8/12)的复发发生在此期间。移植后1个月骨髓ddPCR-MRD水平具有预后意义,以0.465%为界可有效分层总生存、无事件生存和累积复发率。

要点

  • ddPCR比传统方法更早检测到JMML移植后复发表现。
  • 移植后1至3个月为检测分子复发的关键窗口,66.7%(8/12)复发发生在此期间。
  • 移植后1个月骨髓ddPCR-MRD以0.465%为界可分层总生存、无事件生存和累积复发率。

核心结论

  • 本研究强调ddPCR在JMML移植后MRD监测中的优越性,为JMML MRD动态变化提供见解,为JMML的有效管理提供指导。

研究设计与样本

  • 回顾性研究,采用微滴数字PCR(ddPCR)技术监测32例JMML患者的MRD。

主要发现

  • ddPCR检测到复发表现早于传统方法,并揭示JMML MRD动态的分子层面信息。
  • 移植后1至3个月为检测分子复发的关键窗口,66.7%(8/12)的复发发生在此期间。
  • 移植后MRD清除缓慢,65%(13/20)的非复发患者需超过6个月才达到ddPCR-MRD阴性。
  • 移植后1个月骨髓ddPCR-MRD水平具有预后意义,复发患者该时间点ddPCR-MRD水平显著升高(p = 0.026)。
  • 以0.465%为界可有效分层总生存(p = 0.007)、无事件生存(p = 0.035)和累积复发率(p = 0.035)。

关键数值与推荐

  • 移植后1个月骨髓ddPCR-MRD以0.465%为界分层总生存(p = 0.007)、无事件生存(p = 0.035)和累积复发率(p = 0.035)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Juvenile myelomonocytic leukaemia (JMML) is a rare myeloproliferative neoplasm requiring haematopoietic stem cell transplantation (HSCT) for potential cure. Relapse poses a significant obstacle to JMML HSCT treatment, as the lack of effective minimal residual disease (MRD)-monitoring methods leads to delayed interventions. This retrospective study utilized the droplet digital PCR (ddPCR) technique, a highly sensitive nucleic acid detection and quantification technique, to monitor MRD in 32 JMML patients. The results demonstrated that ddPCR detected relapse manifestations earlier than traditional methods and uncovered molecular insights into JMML MRD dynamics. The findings emphasized a critical 1- to 3-month window post-HSCT for detecting molecular relapse, with 66.7% (8/12) of relapses occurring within this period. Slow MRD clearance post-HSCT was observed, as 65% (13/20) of non-relapse patients took over 6 months to achieve ddPCR-MRD negativity. Furthermore, bone marrow ddPCR-MRD levels at 1-month post-HSCT proved to be prognostically significant. Relapsed patients exhibited significantly elevated ddPCR-MRD levels at this time point (p = 0.026), with a cut-off of 0.465% effectively stratifying overall survival (p = 0.007), event-free survival (p = 0.035) and cumulative incidence of relapse (p = 0.035). In conclusion, this study underscored ddPCR's superiority in JMML MRD monitoring post-HSCT. It provided valuable insights into JMML MRD dynamics, offering guidance for the effective management of JMML.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Mao S, Lin Y, Qin X, et al. Droplet digital PCR: An effective method for monitoring and prognostic evaluation of minimal residual disease in JMML. Br J Haematol. 2024. PMID: 38622924. doi:10.1111/bjh.19465

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。